25 Apr 2026 bundleStory 33 of 29

SCIENCEMEDIUM PRIORITYUPSC · LowSSC · HighBanking · LowRailway · HighDefence · Low

GENE DRIVE TECHNOLOGY — a genetic engineering approach being explored for malaria control — uses the CRISPR-Cas9 system to ensure that an engineered gene is inherited by more than 90% of offspring (versus the natural ~50%), enabling rapid spread through mosquito populations; two pathways are being developed: (1) POPULATION SUPPRESSION — disrupts genes essential for female mosquito development or fertility, causing populations to shrink or collapse; (2) POPULATION MODIFICATION (replacement) — leaves mosquitoes alive but carrying genes that prevent malaria parasites from developing inside them; both approaches aim to block transmission of the malaria parasite to humans, addressing limitations of conventional control like growing insecticide resistance, but raise ecological, ethical, and biosafety concerns about deliberate alteration or elimination of wild species.

जीन ड्राइव प्रौद्योगिकी — मलेरिया नियंत्रण के लिए खोजा जा रहा एक आनुवंशिक इंजीनियरिंग दृष्टिकोण — CRISPR-Cas9 प्रणाली का उपयोग यह सुनिश्चित करने के लिए करती है कि एक इंजीनियर किया गया जीन 90% से अधिक संतानों द्वारा विरासत में मिले (प्राकृतिक ~50% के विरुद्ध), जिससे मच्छर आबादी के माध्यम से तेज़ी से प्रसार सक्षम हो; दो मार्ग विकसित किए जा रहे हैं: (1) जनसंख्या दमन — मादा मच्छर के विकास अथवा प्रजनन क्षमता के लिए आवश्यक जीन को बाधित करता है, आबादी को सिकोड़ता अथवा ध्वस्त करता है; (2) जनसंख्या संशोधन (प्रतिस्थापन) — मच्छरों को जीवित रखता है लेकिन उनमें ऐसे जीन ले जाते हैं जो मलेरिया परजीवियों को उनके अंदर विकसित होने से रोकते हैं; दोनों दृष्टिकोणों का उद्देश्य मनुष्यों में मलेरिया परजीवी के संचरण को अवरुद्ध करना है, बढ़ती कीटनाशक प्रतिरोध सहित पारंपरिक नियंत्रण की सीमाओं को संबोधित करना, लेकिन जंगली प्रजातियों के जानबूझकर परिवर्तन अथवा उन्मूलन के बारे में पारिस्थितिक, नैतिक, एवं जैव-सुरक्षा चिंताएँ उठाते हैं।

25 April 2026·Reportage on gene drive technology for malaria control — explainer covering CRISPR-Cas9 mechanism, biased inheritance, population suppression and modification pathways, benefits and risks

Why in News

Malaria remains a major global health challenge — and increasingly faces resistance issues with conventional control methods (insecticides for vectors, antimalarial drugs for parasites). This is prompting exploration of genetic solutions like GENE DRIVES. NORMALLY, a gene passes to 50% of offspring (Mendelian inheritance). A GENE DRIVE INCREASES THIS TO MORE THAN 90%, allowing the gene to spread very quickly through a population. MECHANISM: A gene drive uses the CRISPR-Cas9 system, where a protein (Cas9) cuts the mosquito's DNA at a specific site. The cell repairs the cut using the modified gene as a template, forcing it to copy the 'drive sequence' into BOTH DNA strands (instead of just one as would happen in normal inheritance). This ensures the modified gene is passed to most offspring (>90%) and spreads rapidly in mosquito populations. TWO PATHWAYS: (1) POPULATION SUPPRESSION — these drives disrupt genes essential for female mosquitoes to develop or become fertile; as the drive spreads, more females become sterile, causing mosquito populations to shrink or collapse. (2) POPULATION MODIFICATION (replacement) — in these drives, mosquitoes remain alive but carry genes that prevent the malaria parasites from developing inside their bodies. The 5-STEP PROCESS by which gene drive helps malaria control: STEP 1 — GENETIC ENGINEERING (scientists change mosquito genes so they either cannot reproduce properly or cannot carry malaria parasites); STEP 2 — BIASED INHERITANCE (changed genes passed to >90% of offspring); STEP 3 — POPULATION SPREAD (over generations, more mosquitoes carry the modified gene); STEP 4A — SUPPRESSION PATHWAY (female mosquitoes become sterile, population reduced) OR STEP 4B — MODIFICATION PATHWAY (mosquitoes produce substances that kill or stop malaria parasites inside them); STEP 5 — TRANSMISSION BLOCK (parasites cannot grow to infectious stage, so mosquitoes cannot spread malaria to humans). TARGET MOSQUITO SPECIES: gene-drive research focuses primarily on Anopheles mosquitoes — particularly Anopheles gambiae and Anopheles stephensi (the latter being the main vector for urban malaria in South Asia including India). KEY CONCERNS: (a) ECOLOGICAL — irreversible alteration or elimination of wild species; cascading effects on food chains; (b) BIOSAFETY — risk of cross-breeding with related non-target species; (c) ETHICAL — deliberate human-driven extinction of a species, even a disease-vector species, raises moral questions; (d) GOVERNANCE — international coordination needed since mosquitoes do not respect borders; (e) RESISTANCE — mosquitoes may evolve resistance to the gene drive itself over generations; (f) PUBLIC ACCEPTANCE — communities need to consent to releases of genetically engineered organisms. CURRENT REGULATORY CONTEXT: WHO's 2021 guidance framework supports continued research with stringent biosafety; the Cartagena Protocol on Biosafety (2000) under the Convention on Biological Diversity governs transboundary movement of living modified organisms (LMOs); India is a signatory. Field trials of gene drive mosquitoes have been small and contained; large-scale releases remain hypothetical pending regulatory clearance.

At a Glance

Technology: Gene drive — a genetic engineering approach for spreading a modified gene rapidly through a wild population
Application: Malaria control — alternative/complement to conventional vector control
Core method: CRISPR-Cas9 system — Cas9 protein cuts DNA at specific site; cell copies modified 'drive sequence' into both DNA strands
Inheritance ratio: Natural: ~50% offspring (Mendelian); Gene drive: >90% offspring (biased inheritance)
Pathway 1 — Population suppression: Disrupt genes essential for female mosquito development or fertility → mosquito populations shrink or collapse
Pathway 2 — Population modification: Mosquitoes remain alive but carry genes that prevent malaria parasites from developing inside them
5-step process: (1) Genetic engineering (2) Biased inheritance (3) Population spread (4A or 4B suppression/modification) (5) Transmission block
Target species (primary): Anopheles mosquitoes — including A. gambiae and A. stephensi (urban malaria vector in South Asia)
Key benefits: Faster than conventional vector control; addresses growing insecticide resistance; potentially long-lasting
Key concerns: Ecological cascades, biosafety, ethics, transboundary governance, resistance evolution, public acceptance
International framework: Cartagena Protocol on Biosafety (2000) under CBD — governs transboundary movement of LMOs; India is signatory
WHO guidance: Supports continued gene-drive research with stringent biosafety and stakeholder engagement

Key Fact

Malaria remains a MAJOR GLOBAL HEALTH CHALLENGE — and increasingly faces resistance with conventional control methods (insecticides for vectors, antimalarial drugs for parasites). This is prompting exploration of genetic solutions like GENE DRIVES. NORMAL INHERITANCE (Mendelian): a gene passes to 50% of offspring. GENE DRIVE INHERITANCE: the engineered gene passes to MORE THAN 90% of offspring — allowing it to spread very quickly through a wild population. MECHANISM (using CRISPR-Cas9 system): The CAS9 PROTEIN cuts the mosquito's DNA at a specific site. The cell then repairs this cut using the modified gene as a template, forcing it to COPY THE 'DRIVE SEQUENCE' INTO BOTH DNA STRANDS (instead of just one strand as would happen in normal inheritance). This ensures the modified gene is passed to most offspring (>90%), allowing it to spread rapidly in mosquito populations. TWO STRATEGIC PATHWAYS for gene-drive-based malaria control: (1) POPULATION SUPPRESSION — these drives disrupt genes essential for FEMALE MOSQUITOES to develop or become fertile (only female mosquitoes bite humans and transmit malaria); as the drive spreads, more females become sterile, causing mosquito populations to SHRINK OR COLLAPSE. (2) POPULATION MODIFICATION (also called replacement) — in these drives, mosquitoes REMAIN ALIVE but carry genes that prevent the MALARIA PARASITES from developing inside their bodies. THE 5-STEP PROCESS for gene-drive malaria control: STEP 1 — GENETIC ENGINEERING (scientists change mosquito genes so they either cannot reproduce properly OR cannot carry malaria parasites); STEP 2 — BIASED INHERITANCE (changed genes passed to >90% of offspring instead of half, so they spread very fast); STEP 3 — POPULATION SPREAD (over generations, more and more mosquitoes carry the modified gene, making it common in the population); STEP 4A — SUPPRESSION PATHWAY (if reproduction is affected, female mosquitoes become sterile, mosquito population reduced) OR STEP 4B — MODIFICATION PATHWAY (if parasites are targeted, mosquitoes produce substances that kill or stop malaria parasites inside them); STEP 5 — TRANSMISSION BLOCK (parasites cannot grow to the infectious stage, so mosquitoes cannot spread malaria to humans). TARGET MOSQUITO SPECIES: gene-drive research focuses primarily on ANOPHELES MOSQUITOES — particularly ANOPHELES GAMBIAE (main African malaria vector) and ANOPHELES STEPHENSI (main urban malaria vector in South Asia including India and parts of the Arabian Peninsula). MALARIA CONTEXT: Malaria is caused by PLASMODIUM PARASITES (P. falciparum, P. vivax, P. malariae, P. ovale, P. knowlesi) transmitted to humans by infected female Anopheles mosquitoes. According to WHO World Malaria Report 2024, there were approximately 263 million malaria cases globally with about 597,000 deaths in 2023; sub-Saharan Africa accounted for ~95% of cases and deaths. India has made significant progress on malaria reduction under the National Vector Borne Disease Control Programme (NVBDCP, integrated under National Centre for Vector Borne Diseases Control / NCVBDC). KEY POLICY CONCERNS with gene drives: (a) ECOLOGICAL CONCERNS — irreversible alteration or elimination of wild species; cascading effects on food chains (e.g., other species that feed on mosquitoes); (b) BIOSAFETY — risk of cross-breeding with related non-target species; horizontal gene transfer concerns; (c) ETHICAL — deliberate human-driven elimination of a species, even a disease vector, raises moral questions; (d) GOVERNANCE — mosquitoes don't respect borders, so international coordination is needed before any open release; (e) RESISTANCE EVOLUTION — mosquitoes may evolve resistance to the gene drive itself over generations, similar to how insecticide resistance has emerged; (f) PUBLIC ACCEPTANCE — communities need informed consent before releases of genetically engineered organisms in their habitat. INTERNATIONAL REGULATORY FRAMEWORK: (1) the CARTAGENA PROTOCOL ON BIOSAFETY (2000) under the CONVENTION ON BIOLOGICAL DIVERSITY (CBD) — governs transboundary movement, transit, handling, and use of LIVING MODIFIED ORGANISMS (LMOs) that may have adverse effects on biodiversity; India is a signatory and has ratified the Protocol. (2) The WORLD HEALTH ORGANIZATION (WHO) issued guidance in 2021 supporting continued gene-drive research with stringent biosafety, ethical review, and stakeholder engagement. INDIA'S BIOSAFETY ARCHITECTURE: (i) Genetic Engineering Appraisal Committee (GEAC) under MoEFCC — apex regulator for environmental release of genetically engineered organisms; (ii) Department of Biotechnology (DBT) under Ministry of Science and Technology — promotes biotech research; (iii) Review Committee on Genetic Manipulation (RCGM) — oversees recombinant DNA research; (iv) Institutional Biosafety Committees (IBSCs) at research institutions. FIELD TRIALS of gene-drive mosquitoes have been SMALL AND CONTAINED so far; LARGE-SCALE RELEASES remain hypothetical pending regulatory clearance. The TARGET MALARIA project (a research consortium funded by Bill & Melinda Gates Foundation and others) has been working on gene-drive mosquitoes for African malaria control for over a decade. India's approach to gene-drive research has been cautious but research is ongoing. For SSC, Railway, and State PCS exams, this topic intersects: biotechnology basics (CRISPR-Cas9), public health policy, biosafety regulation, ethics in science, India's vector-borne disease control, and international biosafety treaties.

जीन ड्राइव प्रौद्योगिकी मलेरिया नियंत्रण के लिए खोजा जा रहा एक आनुवंशिक इंजीनियरिंग दृष्टिकोण है। सामान्य विरासत: एक जीन 50% संतानों को मिलता है (मेंडेलियन)। जीन ड्राइव विरासत: इंजीनियर किया गया जीन 90% से अधिक संतानों को मिलता है। तंत्र: CRISPR-Cas9 प्रणाली का उपयोग; Cas9 प्रोटीन एक विशिष्ट स्थान पर मच्छर के DNA को काटता है; कोशिका संशोधित जीन को टेम्पलेट के रूप में उपयोग करके कट को मरम्मत करती है, 'ड्राइव अनुक्रम' को दोनों DNA स्ट्रैंड में कॉपी करने के लिए मजबूर करती है। दो रणनीतिक मार्ग: (1) जनसंख्या दमन — मादा मच्छर विकास/प्रजनन के लिए आवश्यक जीन को बाधित करता है; आबादी सिकुड़ती/ध्वस्त होती है। (2) जनसंख्या संशोधन (प्रतिस्थापन) — मच्छर जीवित रहते हैं लेकिन ऐसे जीन ले जाते हैं जो मलेरिया परजीवियों को विकसित होने से रोकते हैं। 5-चरण प्रक्रिया: (1) आनुवंशिक इंजीनियरिंग (2) पक्षपाती विरासत (3) जनसंख्या प्रसार (4A दमन / 4B संशोधन) (5) संचरण अवरोध। लक्ष्य मच्छर: एनोफ़िलीज़ (विशेष रूप से A. gambiae अफ़्रीकी, A. stephensi दक्षिण एशियाई शहरी मलेरिया वाहक)। मलेरिया वैश्विक: 263 मिलियन मामले + 597,000 मौतें (WHO 2024); उप-सहारा अफ़्रीका में ~95%। चिंताएँ: पारिस्थितिक, जैव-सुरक्षा, नैतिक, शासन, प्रतिरोध, सार्वजनिक स्वीकृति। ढाँचा: कार्टाजेना प्रोटोकॉल जैव-सुरक्षा 2000 (CBD); WHO 2021 दिशानिर्देश; भारत में GEAC (पर्यावरण मंत्रालय) + DBT + RCGM + IBSCs।

Gene drive — at a glance

जीन ड्राइव — एक नज़र में

>90%

Gene drive offspring inheritance

जीन ड्राइव विरासत

50%

Normal Mendelian inheritance

सामान्य मेंडेलियन

CRISPR-Cas9

Core gene-editing system

मुख्य जीन-संपादन प्रणाली

263M cases

Global malaria 2023 (~597K deaths)

वैश्विक मलेरिया 2023

Gene drive — 5-step process

जीन ड्राइव — 5-चरण प्रक्रिया

How gene drive helps malaria control

जीन ड्राइव कैसे मदद करता है

1. Genetic engineering
1. आनुवंशिक इंजीनियरिंग
Change mosquito genes — cannot reproduce or cannot carry malaria parasites· मच्छर जीन बदलें
2. Biased inheritance
2. पक्षपाती विरासत
>90% offspring inherit (vs 50% normal)· >90% संतान
3. Population spread
3. जनसंख्या प्रसार
Over generations, modified gene becomes common· पीढ़ियों में फैलाव
4A. Suppression pathway
4A. दमन मार्ग
Female mosquitoes sterile → population reduced· मादा बंध्य → आबादी कम
4B. Modification pathway
4B. संशोधन मार्ग
Mosquitoes produce substances that kill/stop malaria parasites· मलेरिया परजीवी रोकें
5. Transmission block
5. संचरण अवरोध
Parasites cannot grow to infectious stage; no human transmission· मनुष्यों में संचरण नहीं

Suppression vs Modification pathway

दमन बनाम संशोधन

Aspect पहलू	Suppression दमन	Modification (replacement) संशोधन
Target लक्ष्य	Female mosquito development/fertility genes मादा विकास/प्रजनन जीन	Genes preventing malaria parasites परजीवी रोकने वाले जीन
Effect on mosquitoes मच्छरों पर प्रभाव	Population shrinks or collapses आबादी सिकुड़ती/ध्वस्त	Population alive but cannot transmit malaria जीवित लेकिन संचरण नहीं
Mechanism for malaria block मलेरिया अवरोध तंत्र	Fewer female mosquitoes overall कम मादा मच्छर	Mosquito immune system kills parasites मच्छर प्रतिरक्षा परजीवी मारती
Ecological footprint पारिस्थितिक पदचिह्न	Eliminates vector species locally वाहक प्रजाति समाप्त	Vector retained, parasite cycle broken वाहक बना रहता

Static GK

•Gene drive: Genetic engineering technology that ensures an engineered gene is inherited by >90% of offspring (vs natural ~50% Mendelian inheritance), enabling rapid spread of the gene through a wild population
•CRISPR-Cas9: Gene-editing system originally derived from bacterial immune defence; CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a DNA sequence; Cas9 is the enzyme protein that cuts DNA at the targeted site; awarded 2020 Nobel Prize in Chemistry to Emmanuelle Charpentier and Jennifer Doudna
•Mendelian inheritance (background): Discovered by Gregor Mendel (1822-1884); each parent passes one of two alleles for a gene to the offspring with 50% probability; gene drive deliberately disrupts this 50% baseline
•Anopheles mosquito: Genus of mosquitoes that includes the main vectors of human malaria; only adult FEMALE Anopheles bite humans and transmit Plasmodium parasites; over 460 species globally, ~70 are competent malaria vectors
•Anopheles gambiae: Primary malaria vector in sub-Saharan Africa; principal target of gene-drive research for population suppression in African contexts
•Anopheles stephensi: Major URBAN malaria vector in South Asia (including India) and parts of Arabian Peninsula; recently spread to East Africa raising new concern for urban African malaria
•Plasmodium parasites: Genus of unicellular protozoan parasites that cause malaria; five species infect humans — P. falciparum (most lethal), P. vivax (most widespread, including India), P. malariae, P. ovale, P. knowlesi (zoonotic)
•World malaria burden (WHO 2024 World Malaria Report): Approximately 263 million cases globally + ~597,000 deaths in 2023; sub-Saharan Africa accounts for ~95% of cases and deaths; children under 5 are particularly vulnerable
•India's malaria control programme: National Vector Borne Disease Control Programme (NVBDCP) reorganised as National Centre for Vector Borne Diseases Control (NCVBDC) under Ministry of Health and Family Welfare; India committed to malaria elimination by 2030
•Cartagena Protocol on Biosafety: International treaty under the Convention on Biological Diversity (CBD); adopted 29 January 2000 in Montreal; entered into force 11 September 2003; governs transboundary movement, transit, handling, and use of Living Modified Organisms (LMOs); India is a Party
•Genetic Engineering Appraisal Committee (GEAC): Apex Indian regulator for environmental release of genetically engineered organisms; functions under the Ministry of Environment, Forest and Climate Change (MoEFCC); statutory body under the Environment Protection Act, 1986; reviews proposals for field trials and commercial release
•Department of Biotechnology (DBT): Department under the Ministry of Science and Technology, Government of India; established 1986; promotes and funds biotech research and human resources; nodal department for biosafety guidelines and policy
•Review Committee on Genetic Manipulation (RCGM): Committee under DBT that oversees research and development of recombinant DNA-based products; provides authorisation for confined trials of GE organisms; reports findings to GEAC for environmental-release decisions
•Institutional Biosafety Committees (IBSCs): Committees at research institutions in India that review and oversee biosafety aspects of GE research; report to RCGM/GEAC; first-level institutional gatekeepers
•Target Malaria: International research consortium working on gene-drive mosquitoes for African malaria control; funded by Bill & Melinda Gates Foundation and others; has conducted contained-laboratory and small-scale field studies
•Living Modified Organisms (LMOs): Term used in the Cartagena Protocol for organisms whose genetic material has been altered using modern biotechnology; broader than 'Genetically Modified Organisms' (GMOs) in some legal usages

Timeline

1860s
Gregor Mendel describes principles of inheritance — foundation of genetics.
1897
Ronald Ross demonstrates that mosquitoes transmit malaria — Nobel Prize 1902.
1987
CRISPR sequences first identified in bacterial genomes.
29 January 2000
Cartagena Protocol on Biosafety adopted in Montreal under the Convention on Biological Diversity.
11 September 2003
Cartagena Protocol on Biosafety enters into force.
2012-13
CRISPR-Cas9 demonstrated as a programmable gene-editing tool by Charpentier, Doudna, and others.
2015
First gene-drive demonstrations in mosquitoes published — sparking biosafety policy debate.
2020
Nobel Prize in Chemistry awarded to Emmanuelle Charpentier and Jennifer Doudna for CRISPR-Cas9.
2021
WHO issues guidance framework supporting continued gene-drive research with stringent biosafety.
2023
WHO World Malaria Report estimates ~263 million cases + ~597,000 deaths globally.
2026
Reportage on gene-drive technology for malaria control — mechanism explainer covering CRISPR-Cas9 process, two pathways (suppression/modification), and 5-step framework.

Mnemonic · Memory Hooks

→Technology = GENE DRIVE = a genetic engineering approach for SPREADING modified genes RAPIDLY through wild populations.
→Application = MALARIA CONTROL.
→Core method = CRISPR-Cas9 system. Cas9 = protein that CUTS DNA at specific site. Cell repairs cut by COPYING DRIVE SEQUENCE into BOTH DNA STRANDS.
→Inheritance ratio: NORMAL (Mendelian) = 50% offspring. GENE DRIVE = >90% offspring.
→TWO PATHWAYS: (1) POPULATION SUPPRESSION — disrupt genes essential for FEMALE MOSQUITO development/fertility; populations shrink or collapse. (2) POPULATION MODIFICATION (replacement) — mosquitoes alive but carry genes preventing MALARIA PARASITES from developing inside them.
→Only FEMALE Anopheles mosquitoes bite humans and transmit malaria — so suppression targets females.
→5-STEP PROCESS: (1) Genetic Engineering — change mosquito genes (2) Biased Inheritance — >90% offspring inherit (3) Population Spread — over generations more carry modified gene (4A) Suppression Pathway OR (4B) Modification Pathway (5) Transmission Block — parasites cannot grow to infectious stage.
→Target species: ANOPHELES mosquitoes. Primary: A. GAMBIAE (Africa) + A. STEPHENSI (urban malaria, South Asia incl India + recently spread to East Africa).
→Malaria caused by PLASMODIUM parasites — 5 human-infecting species: P. falciparum (most lethal), P. vivax (most widespread incl India), P. malariae, P. ovale, P. knowlesi (zoonotic).
→WHO World Malaria Report 2024 (data for 2023): ~263 MILLION cases globally + ~597,000 deaths. Sub-Saharan Africa = ~95% of cases and deaths.
→India: National Vector Borne Disease Control Programme (NVBDCP) → reorganised as National Centre for Vector Borne Diseases Control (NCVBDC). Under MoHFW. Target: MALARIA ELIMINATION BY 2030.
→RONALD ROSS demonstrated mosquitoes transmit malaria in 1897. Nobel Prize 1902.
→CRISPR-Cas9 = NOBEL PRIZE in CHEMISTRY 2020 to EMMANUELLE CHARPENTIER + JENNIFER DOUDNA.
→International framework: CARTAGENA PROTOCOL on BIOSAFETY (under Convention on Biological Diversity / CBD). Adopted 29 JAN 2000 Montreal. In force 11 SEP 2003. Governs LMOs (Living Modified Organisms). INDIA = Party.
→WHO 2021 guidance = supports continued gene-drive research with STRINGENT BIOSAFETY + ethical review + stakeholder engagement.
→India's BIOSAFETY ARCHITECTURE: (1) GEAC = Genetic Engineering Appraisal Committee — APEX regulator. Under MoEFCC. Statutory under Environment Protection Act 1986. (2) DBT = Department of Biotechnology. Under Min of Science & Tech. Established 1986. (3) RCGM = Review Committee on Genetic Manipulation under DBT. (4) IBSCs = Institutional Biosafety Committees at research institutions.
→TARGET MALARIA = international research consortium for gene-drive mosquitoes for African malaria control. Funded by Bill & Melinda Gates Foundation.
→KEY CONCERNS: (1) Ecological — irreversible alteration/elimination of species; cascading food-chain effects (2) Biosafety — cross-breeding with non-targets (3) Ethical (4) Governance — mosquitoes don't respect borders (5) Resistance evolution to drive itself (6) Public acceptance.
→Field trials = SMALL AND CONTAINED so far. Large-scale releases = HYPOTHETICAL pending regulatory clearance.

Exam Angles

SSC / Railway

Gene drive technology — being explored for malaria control — uses the CRISPR-Cas9 system to ensure an engineered gene is inherited by more than 90% of offspring (vs natural 50% Mendelian inheritance), enabling rapid spread through Anopheles mosquito populations; two pathways are pursued: (1) population suppression (disrupting female-mosquito development/fertility genes; populations shrink or collapse) and (2) population modification (mosquitoes alive but carry genes preventing Plasmodium parasites from developing inside them); 5-step process: genetic engineering → biased inheritance → population spread → suppression OR modification → transmission block; international framework via the Cartagena Protocol on Biosafety (2000, under CBD); India's biosafety regulator is GEAC under MoEFCC.

Common Confusions

Trap · Mendelian vs gene drive inheritance ratio
Correct: MENDELIAN (normal) inheritance = 50% of offspring inherit a gene. GENE DRIVE inheritance = MORE THAN 90% of offspring. Don't confuse with 75% or 100%. The biased inheritance is the defining feature of gene drives.
Trap · CRISPR vs Cas9 — what each one is
Correct: CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats — a DNA SEQUENCE pattern originally found in bacterial genomes. Cas9 = the ENZYME PROTEIN that cuts DNA at a targeted site. CRISPR-Cas9 system = the combination used for gene editing.
Trap · CRISPR-Cas9 Nobel Prize
Correct: Nobel Prize in CHEMISTRY (NOT Physiology or Medicine) — 2020 — to EMMANUELLE CHARPENTIER and JENNIFER DOUDNA for development of CRISPR-Cas9 method for genome editing.
Trap · Suppression vs modification pathway
Correct: SUPPRESSION = disrupt FEMALE mosquito development/fertility genes → population SHRINKS or COLLAPSES. MODIFICATION (replacement) = mosquitoes ALIVE but carry genes that PREVENT MALARIA PARASITES from developing. Two distinct strategies — don't conflate.
Trap · Why females targeted in suppression pathway
Correct: Only FEMALE Anopheles mosquitoes BITE HUMANS and TRANSMIT MALARIA. Males feed on plant nectar, not blood. Suppressing female fertility/development directly reduces transmission. Don't say males also bite humans.
Trap · Anopheles gambiae vs A. stephensi range
Correct: A. GAMBIAE = primary vector in SUB-SAHARAN AFRICA (rural). A. STEPHENSI = major URBAN malaria vector in SOUTH ASIA (incl India) and parts of Arabian Peninsula; recently spread to East Africa. Different geographic distributions.
Trap · Plasmodium species — which causes most deaths?
Correct: P. FALCIPARUM = most lethal globally; dominant in Africa. P. VIVAX = most widespread globally; significant in India. Five human-infecting species: P. falciparum, P. vivax, P. malariae, P. ovale, P. knowlesi (zoonotic, primarily Southeast Asia).
Trap · Discovery that mosquitoes transmit malaria
Correct: RONALD ROSS in 1897 — demonstrated that mosquitoes transmit malaria. Nobel Prize 1902 (the second Nobel in Physiology or Medicine). NOT Charles Laveran (who discovered Plasmodium parasite in 1880, also Nobel in 1907).
Trap · Cartagena Protocol — adoption vs in-force date
Correct: ADOPTED 29 JANUARY 2000 in MONTREAL. ENTERED INTO FORCE 11 SEPTEMBER 2003. Don't confuse the two dates. Under the Convention on Biological Diversity (CBD).
Trap · Cartagena Protocol — what does it govern?
Correct: Governs TRANSBOUNDARY MOVEMENT, transit, handling, and use of LIVING MODIFIED ORGANISMS (LMOs). NOT genetic resources access (that's Nagoya Protocol). NOT wildlife trade (that's CITES). NOT hazardous waste (that's Basel Convention).
Trap · GEAC affiliation
Correct: Genetic Engineering Appraisal Committee — under MINISTRY OF ENVIRONMENT, FOREST AND CLIMATE CHANGE (MoEFCC). Statutory body under ENVIRONMENT PROTECTION ACT 1986. NOT under DBT (which is under Ministry of Science and Technology and oversees RCGM).
Trap · RCGM vs GEAC
Correct: RCGM = Review Committee on Genetic Manipulation, under DBT (Department of Biotechnology), oversees confined trials of GE organisms. GEAC = Genetic Engineering Appraisal Committee, under MoEFCC, APEX regulator for environmental RELEASE. RCGM reports to GEAC. Different roles, different ministries.
Trap · DBT establishment year
Correct: Department of Biotechnology established 1986 — under Ministry of Science and Technology. NOT 1980 or 1991. Same year as Environment Protection Act 1986.
Trap · WHO World Malaria Report numbers (2023 data)
Correct: Approximately 263 MILLION cases globally + ~597,000 deaths in 2023 (per WHO World Malaria Report 2024). Sub-Saharan Africa = ~95% of cases and deaths. Don't confuse with annual mortality of other diseases.
Trap · India malaria elimination target
Correct: India committed to MALARIA ELIMINATION BY 2030 — under National Vector Borne Disease Control Programme (NVBDCP) / National Centre for Vector Borne Diseases Control (NCVBDC). Under Ministry of Health and Family Welfare. NOT 2025 or 2040.
Trap · LMOs vs GMOs
Correct: In Cartagena Protocol usage, LMO (LIVING MODIFIED ORGANISM) is the formal term — emphasising that the organism is alive and capable of reproducing. GMO (Genetically Modified Organism) is a broader term in common use including non-living modified products. Don't conflate in legal contexts.
Trap · Target Malaria project funding
Correct: Funded primarily by BILL & MELINDA GATES FOUNDATION (and others). International research consortium. NOT a WHO programme directly. Has conducted contained-laboratory and small-scale field studies on gene-drive mosquitoes.

Flashcard

Q · Gene drive technology for malaria control + India biosafety regulation?tap to reveal

A · TECHNOLOGY: GENE DRIVE = genetic engineering approach to ensure modified gene inherited by >90% of offspring (vs 50% Mendelian). APPLICATION: Malaria control. CORE METHOD: CRISPR-Cas9 — Cas9 protein cuts DNA at specific site; cell repairs cut by COPYING DRIVE SEQUENCE into BOTH DNA STRANDS. TWO PATHWAYS: (1) POPULATION SUPPRESSION — disrupt genes essential for FEMALE mosquito development/fertility (only females bite humans); populations SHRINK or COLLAPSE (2) POPULATION MODIFICATION (replacement) — mosquitoes ALIVE but carry genes preventing MALARIA PARASITES from developing inside them. 5-STEP PROCESS: (1) Genetic engineering (2) Biased inheritance (>90%) (3) Population spread over generations (4A) Suppression OR (4B) Modification (5) Transmission block. TARGET SPECIES: ANOPHELES mosquitoes — A. GAMBIAE (Africa) + A. STEPHENSI (urban malaria, South Asia incl India). MALARIA: caused by PLASMODIUM (5 species: P. falciparum most lethal, P. vivax most widespread, P. malariae, P. ovale, P. knowlesi zoonotic). WHO 2024 DATA (for 2023): ~263 million cases + ~597,000 deaths globally; sub-Saharan Africa ~95%. KEY FIGURES: Mendel (1860s, inheritance basics); Ronald Ross (1897, mosquito-malaria, Nobel 1902); CRISPR-Cas9 Nobel CHEMISTRY 2020 (Charpentier + Doudna). INTERNATIONAL FRAMEWORK: CARTAGENA PROTOCOL on BIOSAFETY (under CBD; adopted 29 Jan 2000 Montreal, in force 11 Sep 2003) — governs TRANSBOUNDARY MOVEMENT of LMOs (Living Modified Organisms); India = Party. WHO 2021 guidance supports gene-drive research with stringent biosafety. INDIA'S BIOSAFETY: (1) GEAC = Genetic Engineering Appraisal Committee — APEX regulator; under MoEFCC; statutory under Environment Protection Act 1986 (2) DBT — Dept of Biotechnology under Ministry of Science & Tech; established 1986 (3) RCGM — Review Committee on Genetic Manipulation under DBT (4) IBSCs at research institutions. INDIA TARGET: Malaria elimination by 2030 under NVBDCP/NCVBDC. CONCERNS: Ecological cascades + biosafety + ethics + governance + resistance + public acceptance. Field trials so far: small + contained; large-scale releases hypothetical.